黄色软件免费观看_日本韓國三級國產歐美_在线综合亚洲欧美首页_手机看免费黄色毛片_黄色三级视频_国产 刺激 男女视觉盛宴_在线精品无码字幕无码αv_亚洲香蕉久久国产精品_温客行X周子舒车肉干_日韓歐美一區二區三區免費觀看

Entries by

EISAI PRESENTS LATEST DATA ON BACE INHIBITOR ELENBECESTAT（E2609）AT 9TH CLINICAL TRIALS ON ALZHEIMER’S DISEASE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has presented the latest two clinical trials (Study 202 and Study 006) data on its in-house discovered oral BACE (beta amyloid cleaving enzyme ) inhibitor elenbecestat (development code: E2609) at the 9th Clinical Trials on Alzheimer’s Disease (CTAD 2016) held from December 8 to 10 in San Diego, the United States.

2016/12/12 by

EISAI TO PRESENT LATEST DATA ON ERIBULIN AT 39TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting the latest clinical data on its in-house developed halichondrin class microtubule dynamics inhibitor eribulin mesylate (product name: Halaven?, “eribulin”) will be presented at the San Antonio Breast Cancer Symposium (SABCS2016) taking place in San Antonio, the United States, from December 6 to 10.

2016/11/30 by

EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND RUFINAMIDE AT 70TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest data on its antiepileptic drugs (AED) perampanel (product name: Fycompa?) and rufinamide (product name: Inovelon?, U.S. product name: BANZEL?) will be presented at the 70th American Epilepsy Society (AES) Annual Meeting to be held from December 2 to 6 in Houston in the United States.

2016/11/30 by

U.K. NICE RECOMMENDS ANTICANCER AGENT HALAVEN? AS TREATMENT FOR ADVANCED BREAST CANCER

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its in-house developed anticancer agent Halaven? (eribulin mesylate, “eribulin”) has been recommended by the U.K. National Institute for Health and Clinical Excellence (NICE) as a treatment for patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for advanced disease (prior therapy may have included an anthracycline or a taxane, and capecitabine) in NICE’s Final Appraisal Determination (FAD). Eribulin is the first breast cancer treatment to be recommended by NICE since 2007.?

2016/11/4 by

EISAI TO OFFICIALLY LAUNCH “CHOCOLA BB? RICH CERAMIDE” IN STORES JAPAN

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it will launch its first food with function claims Chocola BB? Rich Ceramide (Notification number: B60) in drugstores, pharmacies and convenience stores throughout Japan on Monday, October 17. The product is Japan’s first drink that is a type of food with function claims containing glucosylceramide derived from rice.

2016/10/17 by

EISAI TO INITIATE PHASE III CLINICAL STUDY OF ANTICANCER AGENT LENVATINIB AS POTENTIAL FIRST-LINE THERAPY FOR ADVANCED RENAL CELL CARCINOMA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.

2016/9/30 by

EISAI TO PRESENT LATEST DATA ON LENVATINIB AND ERIBULIN AT ESMO CONGRESS 2016

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting the latest clinical and pre-clinical data on lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, product name: Lenvima?/Kisplyx?, “l(fā)envatinib”) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven?, “eribulin”) will be presented during the European Society for Medical Oncology (ESMO) Congress 2016, taking place in Copenhagen, Denmark, from October 7 – 11.

2016/9/29 by